Mostrar el registro sencillo del ítem
dc.contributor.author
Fraunhoffer Navarro, Nicolas Alejandro
dc.contributor.author
Meilerman Abuelafia, Analía
dc.contributor.author
Chanez, Brice
dc.contributor.author
Bigonnet, Martin
dc.contributor.author
Gayet, Odile
dc.contributor.author
Roques, Julie
dc.contributor.author
Chuluyan, Hector Eduardo
dc.contributor.author
Dusetti, Nelson
dc.contributor.author
Iovanna, Juan Lucio
dc.date.available
2023-10-05T10:52:58Z
dc.date.issued
2022-09
dc.identifier.citation
Fraunhoffer Navarro, Nicolas Alejandro; Meilerman Abuelafia, Analía; Chanez, Brice; Bigonnet, Martin; Gayet, Odile; et al.; Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity; Wiley; Cancer Communications; 42; 11; 9-2022; 1212-1216
dc.identifier.issn
2523-3548
dc.identifier.uri
http://hdl.handle.net/11336/214158
dc.description.abstract
Pancreatic ductal adenocarcinoma (PDAC) treatmentis focused on two regimens. The polychemotherapy, FOLFIRINOX (folinic acid, fluorouracil, irinotecan, oxali-platin), is used in patients with good health conditions, while gemcitabine, as monotherapy, in patients withpoor health conditions. Gemcitabine resistance-associated pathways have been targeted to sensitize cancercells, but the results were disappointing. Using a transcrip-tomic bioinformatics analysis combined with biologicalvalidation, we showed that glucuronidation was associated with the gemcitabine resistance in PDAC, and its inhibition could switch tumors from resistant to sensitive.To unravel the biological drivers of gemcitabineresponse in PDAC, we determined the transcriptomic dissimilarity between two preclinical models with definedgemcitabine sensitivity.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Wiley
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.subject
CANCER DE PANCREAS
dc.subject
FOLFIRINOX
dc.subject
GEMCITABINE
dc.subject.classification
Patología
dc.subject.classification
Medicina Básica
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2023-07-06T22:40:36Z
dc.identifier.eissn
2523-3548
dc.journal.volume
42
dc.journal.number
11
dc.journal.pagination
1212-1216
dc.journal.pais
Estados Unidos
dc.description.fil
Fil: Fraunhoffer Navarro, Nicolas Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina
dc.description.fil
Fil: Meilerman Abuelafia, Analía. Inserm; Francia
dc.description.fil
Fil: Chanez, Brice. Inserm; Francia
dc.description.fil
Fil: Bigonnet, Martin. Inserm; Francia
dc.description.fil
Fil: Gayet, Odile. Inserm; Francia
dc.description.fil
Fil: Roques, Julie. Inserm; Francia
dc.description.fil
Fil: Chuluyan, Hector Eduardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina
dc.description.fil
Fil: Dusetti, Nelson. Inserm; Francia
dc.description.fil
Fil: Iovanna, Juan Lucio. Inserm; Francia
dc.journal.title
Cancer Communications
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/10.1002/cac2.12365
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1002/cac2.12365
Archivos asociados
Tamaño:
891.3Kb
Formato:
PDF